Esperion Therapeutics, Inc. (ESPR) — 8-K Filings

8-K Filings (21)

• 8-K Filing — Nov 4, 2025
• Esperion Therapeutics Enters Material Definitive Agreement — Oct 8, 2025 Risk: medium
  Esperion Therapeutics, Inc. announced on October 7, 2025, that it has entered into a material definitive agreement. The company, incorporated in Delaware with i
• Esperion Therapeutics Files 8-K — Oct 7, 2025 Risk: low
  Esperion Therapeutics, Inc. filed an 8-K on October 7, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain speci
• Esperion Therapeutics Files 8-K on Financials — Aug 5, 2025 Risk: medium
  Esperion Therapeutics, Inc. filed an 8-K on August 5, 2025, reporting on its results of operations and financial condition. The filing also includes financial s
• Esperion Therapeutics Appoints New CMO, Director — Jul 1, 2025 Risk: medium
  Esperion Therapeutics, Inc. announced on July 1, 2025, the appointment of Dr. Joelle L. Lipton as Chief Medical Officer and the election of Ms. Pamela J. Maragl
• Esperion Therapeutics Files 8-K: Director Changes & Compensation Updates — Jun 2, 2025 Risk: low
  Esperion Therapeutics, Inc. filed an 8-K on May 29, 2025, reporting on the departure of a director, election of a new director, and changes in officer compensat
• Esperion Therapeutics Files 8-K on Financials — May 6, 2025 Risk: low
  Esperion Therapeutics, Inc. filed an 8-K on May 6, 2025, reporting on its results of operations and financial condition. The filing includes financial statement
• Esperion Therapeutics Files 8-K on Officer/Director Changes — Apr 4, 2025 Risk: low
  Esperion Therapeutics, Inc. filed an 8-K on April 4, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointme
• Esperion Therapeutics Files 8-K on Director Changes and Compensation — Apr 1, 2025 Risk: low
  Esperion Therapeutics, Inc. filed an 8-K on April 1, 2025, reporting changes in its board of directors and executive compensation arrangements. The filing also
• Esperion Therapeutics Files 8-K — Mar 4, 2025 Risk: low
  Esperion Therapeutics, Inc. filed an 8-K on March 4, 2025, to report on its results of operations and financial condition, as well as to file financial statemen
• Esperion Therapeutics Files 8-K on Financials — Jan 16, 2025 Risk: low
  Esperion Therapeutics, Inc. filed an 8-K on January 16, 2025, reporting on its results of operations and financial condition as of January 15, 2025. The filing
• Esperion Therapeutics Announces Material Definitive Agreement — Dec 18, 2024 Risk: medium
  On December 17, 2024, Esperion Therapeutics, Inc. entered into a material definitive agreement, likely related to financing or a significant operational change.
• Esperion Therapeutics Amends Credit Agreement with OrbiMed — Dec 13, 2024 Risk: medium
  On December 12, 2024, Esperion Therapeutics, Inc. entered into a Material Definitive Agreement, specifically a Second Amendment to its Credit Agreement with Orb
• Esperion Therapeutics Appoints New Chief Medical Officer — Aug 5, 2024 Risk: low
  Esperion Therapeutics, Inc. announced on August 3, 2024, the appointment of Dr. Joqin V. Diaz as Chief Medical Officer, effective August 5, 2024. Dr. Diaz will
• Esperion Therapeutics Terminates Material Definitive Agreement — Jun 28, 2024 Risk: medium
  On June 27, 2024, Esperion Therapeutics, Inc. announced the termination of its previously entered material definitive agreement with an unnamed party. The compa
• Esperion Therapeutics Files 8-K: Director Changes & More — May 28, 2024 Risk: medium
  Esperion Therapeutics, Inc. filed an 8-K on May 28, 2024, reporting on the departure of a director, election of a new director, and changes to compensatory arra
• Esperion Therapeutics Files 8-K — May 8, 2024 Risk: low
  Esperion Therapeutics, Inc. filed an 8-K on May 8, 2024, to report other events and financial statements. The filing does not contain specific financial figures
• Esperion Files 8-K on Material Agreement; Details Undisclosed — Jan 22, 2024
  Esperion Therapeutics, Inc. filed an 8-K on January 22, 2024, reporting an event on January 18, 2024, related to an "Entry into a Material Definitive Agreement"
• Esperion Therapeutics Files 8-K for Regulation FD Disclosure — Jan 18, 2024
  Esperion Therapeutics, Inc. filed an 8-K on January 18, 2024, primarily to disclose information under Regulation FD, which ensures fair disclosure of material n
• Esperion Therapeutics Files 8-K, Confirms NASDAQ Listing — Jan 11, 2024
  Esperion Therapeutics, Inc. filed an 8-K on January 11, 2024, reporting an event that occurred on January 10, 2024. This filing indicates that the company's Com
• Esperion Therapeutics Files 8-K on Material Definitive Agreement — Jan 3, 2024
  Esperion Therapeutics, Inc. filed an 8-K on January 3, 2024, reporting an "Entry into a Material Definitive Agreement" and "Regulation FD Disclosure" as of Janu

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX